Literature DB >> 15654688

Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.

Eduardo M Diaz1, Richard H Johnigan, Colin Pero, Adel K El-Naggar, Dianna B Roberts, James L Barker, Franco DeMonte.   

Abstract

BACKGROUND: Olfactory neuroblastoma (ONB) is a rare tumor arising from the olfactory neuroepithelium. There is no universally accepted staging system, and treatment approaches lack uniformity. We present one institution's experience with this tumor and the results of therapy.
METHODS: Thirty patients treated for ONB at The University of Texas M. D. Anderson Cancer Center between 1979 and 2002 were retrospectively reviewed. The diagnosis of ONB was histologically confirmed for each patient.
RESULTS: The mean follow-up was 7.32 years. In 77% of cases, patients received treatment with surgery followed by postoperative radiation therapy. Sixteen percent received chemotherapy as part of their initial treatment. Overall 5-year and 10-year survival rates were 89% and 81%, respectively. Nine patients whose disease was initially stage C had a recurrence. The mean time for recurrence was 4.67 years.
CONCLUSIONS: The M. D. Anderson Cancer Center approach to ONB is complete surgical resection, usually involving a craniofacial approach, with postoperative radiation therapy. This approach seems to be curative in early-stage disease. Late recurrence warrants long-term follow-up. 2004 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15654688     DOI: 10.1002/hed.20127

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  45 in total

1.  Salvage Treatment of Local Recurrence in Esthesioneuroblastoma: A Meta-analysis.

Authors:  Mitchell R Gore; Adam M Zanation
Journal:  Skull Base       Date:  2011-01

2.  Feasibility of a robotic surgical approach to reconstruct the skull base.

Authors:  Michael E Kupferman; Franco Demonte; Nicholas Levine; Ehab Hanna
Journal:  Skull Base       Date:  2011-03

Review 3.  Retropharyngeal lymph node metastasis from olfactory neuroblastoma: A report of two cases.

Authors:  Hyun Jik Kim; Jinna Kim; Joo-Heon Yoon
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-12       Impact factor: 2.503

4.  Multimodality Treatment of Pediatric Esthesioneuroblastoma.

Authors:  Rajkumar Venkatramani; Hubert Pan; Wayne L Furman; Jonathan M Marron; Josephine Haduong; Paola Friedrich-Medina; Anita Mahajan; Abhishek Bavle; Hao Wu; Murali Chintagumpala
Journal:  Pediatr Blood Cancer       Date:  2015-10-30       Impact factor: 3.167

5.  Esthesioneuroblastomas: Reservations and Recommendations.

Authors:  Rajesh Nair; Bhavna Nayal; Vinod Kumar; Padmapriya Jaiprakash
Journal:  J Clin Diagn Res       Date:  2016-07-01

6.  Sinonasal Carcinomas with Neuroendocrine Features: Histopathological Differentiation and Treatment Outcomes.

Authors:  Liuba Soldatova; Raewyn G Campbell; Ricardo L Carrau; Daniel M Prevedello; Paul Wakely; Bradley A Otto; Leo F Ditzel Filho
Journal:  J Neurol Surg B Skull Base       Date:  2016-04-26

Review 7.  Olfactory Neuroblastoma.

Authors:  Ahmed S Abdelmeguid
Journal:  Curr Oncol Rep       Date:  2018-02-07       Impact factor: 5.075

Review 8.  Esthesioneuroblastoma: Multimodal management and review of literature.

Authors:  Ritesh Kumar
Journal:  World J Clin Cases       Date:  2015-09-16       Impact factor: 1.337

9.  The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck.

Authors:  Wen Jiang; Abdallah S R Mohamed; Clifton David Fuller; Betty Y S Kim; Chad Tang; G Brandon Gunn; Ehab Y Hanna; Steven J Frank; Shirley Y Su; Eduardo Diaz; Michael E Kupferman; Beth M Beadle; William H Morrison; Heath Skinner; Stephen Y Lai; Adel K El-Naggar; Franco DeMonte; David I Rosenthal; Adam S Garden; Jack Phan
Journal:  Pract Radiat Oncol       Date:  2015-11-10

10.  Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.

Authors:  Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten
Journal:  J Neurooncol       Date:  2009-09-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.